Search for a clinical trial
Other search option(s)
9 Result(s)
Recruiting trial
= 
; Ongoing trial
= 
; Funded by an IRDiRC member = 
National clinical trial(s)
SPAIN
Madrid
ADDRESS: NOT PROVIDED - ES
CCRN 292: A 24-week with possible extension, prospective, multicentre, randomized, double blind, placebo-controlled, 2-parallel group with a randomization 1:1, Phase III study to compare efficacy and safety of masitinib at 6 mg/kg/day to placebo in treatment of patients with Smouldering Systemic, Indolent Systemic or Cutaneous Mastocytosis with handicap - ES (Completed)
Institution: Information not provided - ES
UNITED KINGDOM
Norfolk
NORWICH
CCRN 292: A 24-week with possible extension, prospective, multicentre, randomized, double blind, placebo-controlled, 2-parallel group with a randomization 1:1, Phase III study to compare efficacy and safety of masitinib at 6 mg/kg/day to placebo in treatment of patients with Smouldering Systemic, Indolent Systemic or Cutaneous Mastocytosis with handicap - UK
Norfolk and Norwich University Hospital
GERMANY
Berlin
ADDRESS: NOT PROVIDED - DE
A Phase II Exploratory Study Evaluating the Efficacy of Topical Cromoglicate Solution Compared to Topical Solution Vehicle in the Treatment of Mastocytosis - DE - Prematurely Ended
Institution: Information not provided - DE
GERMANY
Berlin
ADDRESS: NOT PROVIDED - DE
Study on Mastocytosis for Rupatadine Treatment: An Exploratory Phase IV, Randomised, Double-blind, Placebo Controlled Crossover Study to Assess the Efficacy of 20 mg Rupatadine on the Treatment of mastocytosis symptoms
Institution: Information not provided - DE
GERMANY
Berlin
BERLIN
Study on Mastocytosis for Rupatadine Treatment: An Exploratory Phase IV, Randomised, Double-blind, Placebo Controlled Crossover Study to Assess the Efficacy of 20 mg Rupatadine on the Treatment of mastocytosis symptoms
Charité - Universitätsmedizin Berlin
SWITZERLAND
Suisse Alémanique
ZÜRICH
The Effect of Xolair ® (Omalizumab) in Mastocytosis Patients Prospective Double-blind, Placebo-controlled, Multicentre Study, XOLMA-Study
Universitätspital Zürich
Department of Dermatology
FRANCE
ILE-DE-FRANCE
VILLEJUIF
(APL-A-005-02) Phase I - II clinical and pharmacokinetic study of Aplidin (APL) as a 3-hour intravenous infusion every 2 weeks, in children with refractory or relapsed malignant tumours and leukaemia -Terminated -
CLCC Institut Gustave Roussy
Département de Cancérologie de l'enfant et de l'adolescent
BELGIUM
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
STEP: Sorafenib Long Term Extension Program - BE
Cliniques Universitaires UCL Saint-Luc
Pneumologie_Oncologie thoracique
Multinational clinical trial(s)
SPAIN
Madrid
COLMENAR VIEJO